NASDAQ:MIRM - Mirum Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $38.80
  • Forecasted Upside: 94.00 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$20.00
▲ +0.54 (2.77%)

This chart shows the closing price for MIRM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mirum Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MIRM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MIRM

Analyst Price Target is $38.80
▲ +94.00% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is $38.80, with a high forecast of $51.00 and a low forecast of $30.00. The average price target represents a 94.00% upside from the last price of $20.00.

This chart shows the closing price for MIRM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Mirum Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2020
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2020
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2020
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2020
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2021
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2021
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/24/2021
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2021

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/20/2021JPMorgan Chase & Co.Initiated CoverageOverweight$30.00High
9/14/2021HC WainwrightLower Price TargetBuy$52.00 ➝ $51.00High
9/14/2021Raymond JamesLower Price TargetStrong-Buy$52.00 ➝ $51.00High
9/13/2021SVB LeerinkLower Price TargetOutperform$33.00 ➝ $32.00High
8/6/2021HC WainwrightReiterated RatingBuyLow
8/6/2021SVB LeerinkLower Price TargetOutperform$38.00 ➝ $33.00High
7/27/2021HC WainwrightReiterated RatingBuy$15.24High
4/1/2021Robert W. BairdReiterated RatingBuy$30.00Medium
2/8/2021SVB LeerinkInitiated CoverageOutperform$38.00High
11/13/2020Raymond JamesBoost Price TargetStrong-Buy$48.00 ➝ $52.00High
9/9/2020GuggenheimBoost Price TargetBuy$27.00 ➝ $38.00High
9/3/2020HC WainwrightReiterated RatingBuy$52.00High
9/1/2020CitigroupBoost Price TargetBuy$28.00 ➝ $31.00High
8/7/2020Raymond JamesUpgradeOutperform ➝ Strong-Buy$28.00 ➝ $48.00High
8/3/2020HC WainwrightInitiated CoverageBuy$52.00Medium
7/30/2020Piper SandlerInitiated CoverageOverweightHigh
6/24/2020Robert W. BairdInitiated CoverageOutperform$30.00Low
5/8/2020Raymond JamesReiterated RatingOutperform$30.00 ➝ $28.00Low
12/17/2019CitigroupBoost Price TargetBuy$21.00 ➝ $30.00Medium
8/12/2019Roth CapitalInitiated CoverageBuy ➝ Buy$33.00High
8/12/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$28.00High
8/12/2019CitigroupInitiated CoverageBuy ➝ Buy$21.00High
8/12/2019GuggenheimInitiated CoverageBuy ➝ Buy$18.00High
8/12/2019Evercore ISIInitiated CoverageOutperform ➝ Outperform$25.00High
(Data available from 9/23/2016 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/24/2021
  • 3 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/23/2021

Current Sentiment

  • 3 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mirum Pharmaceuticals logo
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
Read More

Today's Range

Now: $20.00
Low: $19.80
High: $20.48

50 Day Range

MA: $15.95
Low: $13.95
High: $19.46

52 Week Range

Now: $20.00
Low: $13.85
High: $26.31

Volume

6,049 shs

Average Volume

110,495 shs

Market Capitalization

$610.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Mirum Pharmaceuticals?

The following sell-side analysts have issued research reports on Mirum Pharmaceuticals in the last year: HC Wainwright, JPMorgan Chase & Co., Raymond James, Robert W. Baird, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for MIRM.

What is the current price target for Mirum Pharmaceuticals?

5 Wall Street analysts have set twelve-month price targets for Mirum Pharmaceuticals in the last year. Their average twelve-month price target is $38.80, suggesting a possible upside of 94.0%. Raymond James has the highest price target set, predicting MIRM will reach $51.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $30.00 for Mirum Pharmaceuticals in the next year.
View the latest price targets for MIRM.

What is the current consensus analyst rating for Mirum Pharmaceuticals?

Mirum Pharmaceuticals currently has 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MIRM will outperform the market and that investors should add to their positions of Mirum Pharmaceuticals.
View the latest ratings for MIRM.

How do I contact Mirum Pharmaceuticals' investor relations team?

Mirum Pharmaceuticals' physical mailing address is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. The company's listed phone number is (650) 667-4085 and its investor relations email address is [email protected] The official website for Mirum Pharmaceuticals is mirumpharma.com.